» Articles » PMID: 18046079

A Comparative Evaluation of Various Methods for Microalbuminuria Screening

Overview
Journal Am J Nephrol
Publisher Karger
Specialty Nephrology
Date 2007 Nov 30
PMID 18046079
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Background/aims: Microalbuminuria is a marker of abnormal vascular response and a predictor of cardiovascular morbidity and mortality. We evaluated a new quantitative office-based method to assess urinary albumin excretion (UAE) and compared it to other established methods.

Methods: Spot urine samples from 165 patients were analyzed at a single study site using the HemoCue system, Clinitek Microalbumin, and Chemstrip Micral test, as well as at a central laboratory, where UAE and creatinine levels were measured. The central laboratory UAE values were used as reference. We evaluated the validity of the HemoCue results and compared them to the respective data for the laboratory albumin-to-creatinine ratio (ACR). Additionally, we assessed, diagnostic sensitivity, specificity, and positive and negative predictive values of all four methods, as well as the reproducibility of the HemoCue measurements.

Results: Linear regression analysis demonstrated a good correlation for the HemoCue system (y = 0.9978x - 1.0217, R2 = 0.904) and ACR (y = 0.0815x + 0.3373, R2 = 0.784). Sensitivity and specificity for microalbuminuria diagnosis were 92 and 98% for HemoCue, 73 and 96% for ACR, 100 and 81% for Clinitek Microalbumin, and 70 and 83% for Chemstrip Micral dipstick, respectively. The correlation coefficient of duplicate HemoCue measurements was r = 0.98 (p < 0.001).

Conclusions: The HemoCue system for microalbuminuria detection was as accurate and precise as laboratory ACR estimations. Its diagnostic performance was much better than that of widely used dipstick methods.

Citing Articles

Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus.

Sacks D, Arnold M, Bakris G, Bruns D, Horvath A, Lernmark A Diabetes Care. 2023; 46(10):e151-e199.

PMID: 37471273 PMC: 10516260. DOI: 10.2337/dci23-0036.


Point-of-care testing technologies for the home in chronic kidney disease: a narrative review.

Bodington R, Kassianides X, Bhandari S Clin Kidney J. 2021; 14(11):2316-2331.

PMID: 34751234 PMC: 8083235. DOI: 10.1093/ckj/sfab080.


The Landscape of Diabetic Kidney Disease in the United States.

Kenrik Duru O, Middleton T, Tewari M, Norris K Curr Diab Rep. 2018; 18(3):14.

PMID: 29457196 PMC: 5817078. DOI: 10.1007/s11892-018-0980-x.


The cost-effectiveness of using chronic kidney disease risk scores to screen for early-stage chronic kidney disease.

Yarnoff B, Hoerger T, Simpson S, Leib A, Burrows N, Shrestha S BMC Nephrol. 2017; 18(1):85.

PMID: 28288579 PMC: 5347833. DOI: 10.1186/s12882-017-0497-6.


Screening for Nephropathy in Diabetes Mellitus: Is Micral-Test Valid among All Diabetics?.

Afifa K, Belguith Asma S, Nabil H, Ahlem B, Mounira S, Kawthar Y Int J Chronic Dis. 2016; 2016:2910627.

PMID: 27294192 PMC: 4887651. DOI: 10.1155/2016/2910627.